Kinetic modelling and in vitro release mechanism of levodopa from sporopollenin-based microcapsules in human blood plasma
RSC Pharmaceutics · 2026 · 3 (3) · 799-808
DOI: 10.1039/d5pm00261c ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Pharmaceutics, 2026. Verfasst von Shwan Abdullah Hamad und 3 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Levodopa (LD) remains the most effective therapy for Parkinson’s disease, but its short plasma half-life requires frequent dosing and causes fluctuating drug levels and motor complications. Controlled delivery systems may help stabilise LD release.
Zitieren
APA
Hamad, S. A., Othman, Z. S., Salih, S. H. H., & Abdullah, T. M. (2026). Kinetic modelling and in vitro release mechanism of levodopa from sporopollenin-based microcapsules in human blood plasma. RSC Pharmaceutics, 3(3), 799-808. https://doi.org/10.1039/d5pm00261c
Vancouver
Hamad SA, Othman ZS, Salih SHH, Abdullah TM. Kinetic modelling and in vitro release mechanism of levodopa from sporopollenin-based microcapsules in human blood plasma. RSC Pharmaceutics. 2026;3(3):799-808. doi:10.1039/d5pm00261c
BibTeX
@article{Hamad2026,
author = {Hamad, Shwan Abdullah and Othman, Zhila Salam and Salih, Shilan Hiwa Hama and Abdullah, Trefa Mohammed},
title = {Kinetic modelling and in vitro release mechanism of levodopa from sporopollenin-based microcapsules in human blood plasma},
journal = {RSC Pharmaceutics},
year = {2026},
volume = {3},
number = {3},
pages = {799--808},
doi = {10.1039/d5pm00261c}
}
EUVIMED